Bayer AG published a transcript of its Q4 and full-year 2025 investor call held on March 4, 2026, attended by CEO Bill Anderson, CFO Wolfgang Nickl, and the heads of Crop Science (Rodrigo Santos), Pharmaceuticals (Stefan Oelrich) and Consumer Health (Julio Triana), alongside analysts in the Q&A. Management said Bayer delivered its upgraded 2025 guidance, reporting sales of EUR 45.5 billion, core EPS of EUR 4.91 and free cash flow of EUR 2.1 billion, while continuing a company-wide transformation that has “roughly half as many layers” and “reduced management by two-thirds,” according to Anderson. The company also emphasized litigation as a key priority, referencing a proposed U.S. nationwide class settlement in glyphosate cases and a pending U.S. Supreme Court process, with Anderson stating, “We await the judge’s ruling, and we’ll be ready for any scenario.” For 2026, Bayer guided to net sales of EUR 45 billion to EUR 47 billion and EBITDA before special items of EUR 9.6 billion to EUR 10.1 billion, with core EPS of EUR 4.30 to EUR 4.80 at constant currencies. Nickl said Bayer expects negative free cash flow of minus EUR 1.5 billion to minus EUR 2.5 billion, driven by “significant litigation-related payouts of around EUR 5 billion,” and noted planned financing would rely on “senior bonds… and instruments receiving equity-credit ratings… and not on the AGM authorized capital increase.” Bayer also announced a core EPS methodology change that will include amortization of certain intangibles, particularly software. Divisionally, Crop Science discussed its profitability improvement program and licensing impacts from resolutions with Corteva, while Pharmaceuticals highlighted continued momentum in launch brands and expected declines in Xarelto and Eylea due to generics and biosimilars. Consumer Health pointed to continued market volatility in the U.S. and China but reiterated its “Road to Billion” strategy. The full transcript can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.
Comments